Similarly, a possible association between CYP2E1 polymorphisms and the risk of glioma was demonstrated.[64] However, there was no research on the precise mechanistic role of CYP2E1 in tumor progression, nor the testing of CYP2E1 as a target in clinical treatment of tumors. The gene discussed is CYP2E1; the disease is central nervous system cancer.